CU20160018A7 - PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODS - Google Patents

PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODS

Info

Publication number
CU20160018A7
CU20160018A7 CUP2016000018A CU20160018A CU20160018A7 CU 20160018 A7 CU20160018 A7 CU 20160018A7 CU P2016000018 A CUP2016000018 A CU P2016000018A CU 20160018 A CU20160018 A CU 20160018A CU 20160018 A7 CU20160018 A7 CU 20160018A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
inhibit
activity
compounds
tyrosine kinase
Prior art date
Application number
CUP2016000018A
Other languages
Spanish (es)
Inventor
Bei Li
Diana Sperger
Dimitrios Stefanidis
Melissa Casteel
Rowchanak Pakdaman
Original Assignee
Gilead Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/048733 external-priority patent/WO2015017460A1/en
Application filed by Gilead Connecticut filed Critical Gilead Connecticut
Publication of CU20160018A7 publication Critical patent/CU20160018A7/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones farmacéuticas que comprenden un compuesto que tiene la fórmula: o una sal farmacéuticamente aceptable del mismo, o un hidrato del mismo, y por lo menos un polímero farmacéuticamente aceptable. La sal farmacéuticamente aceptable del compuesto de la fórmula I o un hidrato del mismo puede ser una sal mesilato, incluyendo, por ejemplo, una sal mono-mesilato o una sal bis-mesilato o un hidrato de las mismas. También se describen métodos para utilizar las composiciones farmacéuticas.Pharmaceutical compositions are described comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of the formula I or a hydrate thereof may be a mesylate salt, including, for example, a mono-mesylate salt or a bis-mesylate salt or a hydrate thereof. Methods for using pharmaceutical compositions are also described.

CUP2016000018A 2013-07-30 2016-02-01 PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODS CU20160018A7 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201313618660A 2013-07-30 2013-07-30
PCT/US2014/048733 WO2015017460A1 (en) 2013-07-30 2014-07-29 Polymorph of syk inhibitors

Publications (1)

Publication Number Publication Date
CU20160018A7 true CU20160018A7 (en) 2016-11-29

Family

ID=56565036

Family Applications (2)

Application Number Title Priority Date Filing Date
CUP2016000019A CU20160019A7 (en) 2013-07-30 2016-02-01 POLYMORPH OF INHIBITORS OF TIROSINA KINASA DEL BAZO (SYK), METHODS OF PREPRATION AND COMPOSITIONS
CUP2016000018A CU20160018A7 (en) 2013-07-30 2016-02-01 PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CUP2016000019A CU20160019A7 (en) 2013-07-30 2016-02-01 POLYMORPH OF INHIBITORS OF TIROSINA KINASA DEL BAZO (SYK), METHODS OF PREPRATION AND COMPOSITIONS

Country Status (1)

Country Link
CU (2) CU20160019A7 (en)

Also Published As

Publication number Publication date
CU20160019A7 (en) 2016-07-29

Similar Documents

Publication Publication Date Title
UY35684A (en) FORMULATION OF INHIBITORS OF THE TYPESIN KINASE OF BAZO (SYK)
DOP2020000102A (en) HELPFUL COMPOUNDS TO INHIBIT CDK7
NI201700020A (en) AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS
CY1122730T1 (en) 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USES
BR112016028288A2 (en) compound, pharmaceutical composition, methods for treating an individual with a disease or condition and for inhibiting kinase, and use of a compound.
EA202091115A1 (en) QUINAZOLINE DERIVATIVES USED FOR HIV TREATMENT
CR20160564A (en) CYCLIC DINUCLEOTIDES AS STING MODULATORS
EA201891024A1 (en) TANK-BINDING KINASE INHIBITOR COMPOUNDS
TR201901312T4 (en) Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein.
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
JO3452B1 (en) Aminoheteroaryl benzamides as kinase inhibitors
EA201791304A1 (en) IZOHINOLINA DERIVATIVES FOR HIV TREATMENT
DK2970216T3 (en) Biarylamide compounds as kinase inhibitors
MX2016006891A (en) Methods useful in the synthesis of halichondrin b analogs.
UY34750A (en) ? COMPOUNDS FOR HIV TREATMENT, COMPOSITIONS, PREPARATION METHODS, INTERMEDIARIES AND THERAPEUTIC METHODS ?.
DOP2016000253A (en) NEW COMPOUNDS
EA201591805A1 (en) OXABICICLO [2.2.2] ACIDS - MODULATORS GPR120
BR112015020139A2 (en) therapeutic compounds and their uses
EA201790627A1 (en) STEMULATORS RHC
EA201600434A1 (en) APPLICATION OF DERIVATIVES OF BENZIMIDAZOLPROLINE
EA201591397A1 (en) CINOXALINONES AND DIHYDROCHINOXALINONS AS ANTI-VIRUS MEANS AGAINST RESPIRATORY-SYNCYTIAL VIRUS
CR20160016A (en) SUBSTITUTED PIRAZOLPIRIDINS
AR094707A1 (en) COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE
EA201890532A1 (en) NEW ANNELED BENZAMIDES
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES